Standard Treatment Sample Clauses

Standard Treatment. Unless otherwise specified in the award, program income received or accruing to the awardee during the period of the award is to be retained by the awardee, added to the funds committed to the project by NSF, and thus used to further project objectives. The awardee has no obligation to NSF with respect to program income received beyond the period of the award. The awardee also shall have no obligation to NSF with respect to program income earned from license fees and royalties for copyrighted material, patents, patent applications, trademarks and inventions produced under an award (see PAPPG Chapter VIII.D.4). However, Patent and Trademark Amendments (35 USC §18) shall apply to inventions made under an award. Efforts should be made to avoid having unexpended program income remaining at the end date of the award. Program income earned during the project period should be expended prior to requesting reimbursement against the award. In the event an awardee has unexpended program income remaining at the end of the award, it must be remitted to NSF by crediting costs otherwise chargeable against the award. If it is not possible to record the credit via ACM$, the excess program income must be remitted to NSF electronically or by check payable to the National Science Foundation.
AutoNDA by SimpleDocs
Standard Treatment. Unless otherwise specified in the award, program income (except as noted in (1) below) received or accrued to the awardee during the period of this award shall be retained and added to the funds committed to the project by NSF and used to further project objectives. Also, unless otherwise specified, the awardee shall have no obligation to NSF with respect to: (1) license fees and royalties for copyrighted material, patents, patent applications, trademarks, and inventions received or accrued at any time; or (2) program income received beyond the period of this award.
Standard Treatment. Unless otherwise specified in the Agreement, program income (except as noted in (1) below) received or accrued to the Subrecipient during the period of this Agreement shall be retained and added to the funds committed to the project by NRAO and used to further project objectives. Also, unless otherwise specified, the Subrecipient shall have no obligation to NRAO with respect to: (1) license fees and royalties for copyrighted material, patents, patent applications, trademarks, and inventions received or accrued at any time; or (2) program income received beyond the period of this Agreement.
Standard Treatment. Unless otherwise specified in the award, program income received or accruing to the awardee during the period of the award is to be retained by the awardee, added to the funds committed to the project by NSF, and thus used to further project objectives. The awardee has no obligation to NSF with respect to program income received beyond the period of the award. The awardee also shall have no obligation to NSF with respect to program income earned from license fees and royalties for copyrighted material, patents, patent applications, trademarks, and inventions produced under an award (see AAG Chapter III.D.4). However, Patent and Trademark Amendments (35 USC 18) shall apply to inventions made under an award. See also FAQ 200.307.1 of the Frequently Asked Questions for The Office of Management and Budget’s Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at 2 CFR § 200 (dated November, 2014) regarding Fees and Royalties and Xxxx-Xxxx. Efforts should be made to avoid having unexpended program income remaining at the end of the award. Program income earned during the project period should be expended prior to requesting reimbursement against the award. In the event an awardee has unexpended program income remaining at the end of the award, it must be remitted to NSF by crediting costs otherwise chargeable against the award. If it is not possible to record the credit via ACM$, the excess program income must be remitted to NSF electronically or by check payable to the National Science Foundation.
Standard Treatment. Unless otherwise specified in the award, program income received or accruing to the awardee during the period of the award is to be retained by the awardee, added to the funds committed to the project by NSF, and thus used to further project objectives. The awardee has no obligation to NSF with respect to program income received beyond the period of the award. The awardee also is not accountable to NSF with respect to program income earned from license fees and royalties for copyrighted material, patents, patent applications, trademarks and inventions made under a Federal Award to which 37 CFR part 401 is applicable (see PAPPG Chapter VIII.D.4). However, Patent and Trademark Amendments (35 USC 18) shall apply to inventions made under an award. Efforts should be made to avoid having unexpended program income remaining at the end of the award. Program income earned during the project period should be expended prior to requesting reimbursement against the award. In the event an awardee has unexpended program income remaining at the end of the award, it must be remitted to NSF by crediting costs otherwise chargeable against the award. If it is not possible to record the credit via ACM$, the excess program income must be remitted to NSF electronically or by check payable to the National Science Foundation.
Standard Treatment. Unless otherwise specified in the award, program income received or accruing to the awardee during the period of the award is to be retained by the awardee, added to the funds committed to the project by NSF, and thus used to further project objectives. The awardee has no obligation to NSF with respect to program income received beyond the period of the award. The awardee also shall have no obligation to NSF with respect to program income earned from license fees and royalties for copyrighted material, patents, patent applications, trademarks and inventions produced under an award (see PAPPG Chapter VIII.D.4). However, Patent and Trademark Amendments (35 USC 18) shall apply to inventions made under an award. See also FAQ

Related to Standard Treatment

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!